Actuate's Elraglusib Shows Near Doubling of Survival in Pancreatic Cancer Subgroups at ASCO
ACTU sits 29% above its 52-week low of $1.58.
Summary
Actuate Therapeutics announced compelling Phase 2 clinical data for its drug Elraglusib at the ASCO Annual Meeting. The data showed significant improvements in median overall survival (mOS) for first-line metastatic pancreatic cancer patients, with KRAS wild-type patients achieving 16.9 months mOS versus 10.1 months with standard therapy, and a near doubling of mOS in P53WT subgroups. This highly positive clinical update for a difficult-to-treat cancer is critical for Actuate, which recently reaffirmed a going concern warning with cash expected to last only until July 2026. These strong results could be instrumental in attracting the financing or partnerships needed to address the company's severe liquidity challenges and advance Elraglusib.
At the time of this announcement, ACTU was trading at $2.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $48.3M. The 52-week trading range was $1.58 to $11.99. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.